JPMorgan upgraded Bioventus (BVS) to Neutral from Underweight with a price target of $13, up from $12. The firm cites better visibility into the company’s growth and several quarters of improved execution for the upgrade. 2024 marked a return to stability for Bioventus, with hyaluronic acid headwinds now lapped and “fully in the rearview and pockets of strength in areas like Ultrasonics,” the analyst tells investors in a research note. As such, JPMorgan feels incrementally more positive about Bioventus into 2025.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BVS: